medicaid coverage for glp 1 MCT2D As demand for weight-loss drugs

That gap matters, but 15% weight loss still represents a transformative result for most people

The long-term safety of semaglutide remains uncertain, and there are concerns about various side effects, including gastrointestinal disturbances, gallbladder events, diabetic retinopathy complications, and potential effects on the heart and kidneys

Review: GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits

At the same time, spending on GLP-1 drugs is rising quickly in public programs such as Medicaid, creating another budget strain for states already dealing with lower alcohol-tax receipts

Understanding what these individual compounds doand more importantly, what they dont doreveals the fundamental problem with GLP-1 booster marketing: the disconnect between what the science shows and what consumers are led to believe

Much is now known about the structure and function of GLP-1R and of its natural ligand GLP-1, while some initial progress has been made in the discovery of non-peptidic agonists